• Globus Medical (NYSE: GMED) has agreed to acquire Synaptive Medical to expand its offering in cranial neurosurgery technologies.
• Synaptive Medical supplies surgical visualization and navigation systems that are used in cranial neurosurgery procedures.
• The deal adds cranial neurosurgery to Globus Medical's enabling technologies portfolio, widening the range of procedures it can support.
• Globus Medical's acquisition of Synaptive Medical is worth weighing against the rest of our findings on the company. Our analysis turns up 5 other big wins for Globus Medical as well.

For a broader view of opportunities in surgical robotics and automation, explore other companies in the sector via 90 robotics and automation stocks.

Globus Medical develops hardware and software for treating musculoskeletal disorders, so moving deeper into cranial neurosurgery extends its reach beyond the spine segment and into more brain-focused procedures, where surgical visualization and navigation systems are already widely used.

Does the team leading Globus Medical have what it takes? See our full breakdown of the management team's track record and compensation.

How does Synaptive Medical fit into Globus Medical's existing platforms?

Globus Medical has focused heavily on musculoskeletal therapies, neuromodulation and its Excelsius robotics ecosystem. Synaptive brings cranial visualization, navigation and planning tools that plug into the same idea of image guided, software heavy procedures. Together, that extends the product set from spine and orthopedics into more brain focused surgery workflows.

Does this change the Globus Medical Narrative investors have been using?

The existing Narrative leans on margin discipline, M&A synergies and a broader digital surgery platform supported by Excelsius and prior deals like NuVasive and Nevro. Synaptive fits that script because it is another acquisition that can feed into enabling technologies, data driven planning and potential manufacturing synergies. The risk side of the Narrative, focused on integration execution and segment volatility, now applies to cranial as well.

See how these catalysts shape Globus Medical's path to a $101 fair value.

What should investors watch next to judge if this acquisition is working?

The key signpost is how cranial neurosurgery solutions show up in Globus Medical's Enabling Technologies and related segment reporting over the next few quarterly updates. Investors can compare those disclosed sales figures with the company’s recent third quarter 2026 revenue of US$763.72 million to gauge whether Synaptive is starting to move the needle.

Add Globus Medical to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.